Outcomes of Non-Ischaemic Coronary Lesions with High-Risk Plaque Characteristics on Coronary CT Angiography

Seokhun Yang,Masahiro Hoshino,Taishi Yonetsu,Jinlong Zhang,Doyeon Hwang,Eun-Seok Shin,Joon-Hyung Doh,Chang-Wook Nam,Jianan Wang,Shaoliang Chen,Nobuhiro Tanaka,Hitoshi Matsuo,Takashi Kubo,Hyuk-Jae Chang,Tsunekazu Kakuta,Bon -Kwon Koo
DOI: https://doi.org/10.4244/eij-d-22-00562
2023-01-01
Abstract:Background: The integrative implications of quantitative and qualitative plaque characteristics on clinical outcomes and therapeutic guidance have not been fully investigated. Aims: We aimed to investigate the combined prognostic value of quantitative and qualitative plaque measures and their interactions with treatment modalities and physiological lesion severity. Methods: Among 697 vessels from 458 patients who underwent fractional flow reserve (FFR)-guided treatment, quantitative high-risk plaque (qn-HRP; plaque burden >= 70% and minimum lumen area <3.3 mm(2)) and qualitative HRP (ql-HRP; low-attenuation plaque or positive remodelling) were defined on coronary computed tomography angiography (CCTA). The primary endpoint was the vessel-oriented composite outcome (VOCO; a composite of cardiac death, myocardial infarction, or revascularisation). Results: The mean baseline FFR was 0.85 +/- 0.12, and 25.8% underwent percutaneous coronary intervention (PCI) during the index procedure. In medically treated lesions, both qn-HRP and ql-HRP were associated with an increased risk of VOCO (p<0.05). Relative to the lesions with qn-HRP(-)/ql-HRP(-),those with qn-HRP(+)/ql-HRP(+) showed a higher risk of VOCO (hazard ratio [HR] 8.36, 95% confidence interval [CI]: 2.86-24.44). The PCI group showed a lower risk for VOCO than the medical treatment group (HR 0.31, 95% CI: 0.11-0.91) in lesions with qn-HRP(+)/ql-HRP(+). This difference was consistent in lesions with an FFR of 0.81-0.90 (HR 0.19, 95 CI: 0.04-0.90), but not in those with an FFR of >0.90. Conclusions: In non-ischaemic lesions, ql-HRP and qn-HRP showed a synergistic impact on risk assessment and had prognostic interactions with FFR and treatment modalities. Therefore, they need to be integrated into risk stratification and the optimisation of a treatment strategy. ClinicalTrials.gov: NCT04037163.
What problem does this paper attempt to address?